03266nas a2200373   4500008004100000020001400041024001700055245014300072210006900215260015200284300001000436490000700446520182200453653006402275653006302339653006602402653001902468653005402487653004402541653001102585653003202596100001902628700002002647700002202667700002402689700001902713700002202732700002302754700002002777700001602797700002002813700001402833856004502847       2005                        eng d  a1592-8721  afyb, 041743500aAcute lung Injury in a healthy donor during mobilization of peripheral blood stem cells using granulocyte-colony stimulating factor alone.0 aAcute lung Injury in a healthy donor during mobilization of peri  aItalybArimura,Kosei. Department of Hematology and Immunology, Kagoshima University Hospital, Sakuragaoka 8-35-1, Kagoshima, 890-8520, Japan.c2005  aECR100 v903 aGranulocyte-colony stimulating factor (G-CSF), a hematopoietic growth factor, is widely used to accelerate recovery from neutropenia after severe chemotherapy, both decreasing the risk of infection and mobilizing peripheral blood stem cells. Adverse effects occur with G-CSF use in approximately 30% of cases, comprised predominantly of bone pain, headache, and general fatigue. Pulmonary toxicity is very rare. Here, we describe a healthy donor for allogeneic hematopoietic stem cell transplantation who developed acute lung injury (ALI) after 4 days of G-CSF administration. Among the serum cytokines examined, only Interleukin (IL)-1beta level was elevated in this case. As a high level of IL-1beta was detected at the onset of ALI, on day 4 after G-CSF administration, and decreased to below the level of detection on day 11, it is possible in a certain part that IL-1beta was involved in the onset of G-CSF-related ALI in the present case. Granulocyte-colony stimulating factor (G-CSF) is commonly administered to healthy donors to mobilize peripheral blood stem cells (PBSC) for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Adverse events from G-CSF use in healthy donors have been described in approximately 30% of cases, and are comprised predominantly of bone pain, headache, and general fatigue. Pulmonary complications caused by G-CSF include cough, dyspnea, and interstitial or alveolar pulmonary edema with mild-to-severe deterioration of blood oxygen level. Few cases of acute respiratory distress syndrome (ARDS) following G-CSF administration have been reported. The present report describes a healthy donor for allo-HSCT with acute lung injury (ALI) after 4 days of G-CSF administration. The cytokine-related mechanisms of G-CSF administration that contribute to ALI are discussed.10a*Granulocyte Colony-Stimulating Factor/ae [Adverse Effects]10a*Hematopoietic Stem Cell Mobilization/ae [Adverse Effects]10a*Respiratory Distress Syndrome, Adult/ci [Chemically Induced]10a*Tissue Donors10aHematopoietic Stem Cell Mobilization/mt [Methods]10aHematopoietic Stem Cell Transplantation10aHumans10aTransplantation, Homologous1 aArimura, Kosei1 aInoue, Hirosaka1 aKukita, Toshimasa1 aMatsushita, Kakushi1 aAkimot, Masaki1 aKawamata, Nakaaki1 aYamaguchi, Akihiko1 aKawada, Hideaki1 aOzak, Atsuo1 aArima, Naomichi1 aTe, Chuwa  uhttp://613633.bywedr.asia/reference/4100